Document:

EXHIBIT 10.149

                               SEVERANCE AGREEMENT

         THIS  AGREEMENT,  made this 20th day of July,  2000, by and
between  Pharmaceutical  Product  Development, Inc. ("PPD") and
Philippe M. Maitre ("Employee").

         WHEREAS, Employee is a valued employee of PPD and in order to induce
Employee to remain in the employ of PPD, PPD desires to provide the severance
benefits hereinafter described in the event of a "Change in Control", as
hereinafter defined, of PPD.

         NOW, THEREFORE, it is agreed as follows:

         1.       Definitions

                  a. "Change in Control" means a change of control of a nature
that would be required to be reported in response to Item 6(e) of Schedule 14A
of Regulation 14A promulgated under the Securities Exchange Act of 1934, as
amended ("Exchange Act"), provided that such a Change in Control shall be deemed
to have occurred if any "person" (as such term is used in Sections 13(d) and
14(d)(2) of the Exchange Act) is or becomes the beneficial owner, directly or
indirectly, of securities of PPD representing 50% or more of the combined voting
power of PPD's then outstanding securities.

                  b. "Constructive Termination" means a termination of
Employee's employment by PPD during the Covered Period initiated by Employee
after (i) a substantial diminution or alteration in the duties of Employee, (ii)
a reduction by PPD in Employee's base salary in effect on the date of the Change
in Control, or (iii) the relocation of Employee's primary work location to a
location that is more than twenty-five (25) miles from Employee's primary work
location prior to the Change in Control. Constructive Termination specifically
does not include termination of Employee by reason of death, Disability or
retirement at or after age 65. Employee shall give PPD written notice of a
Constructive Termination, which notice shall provide a brief description of the
circumstances which Employee asserts gives rise to a right of Constructive
Termination, and PPD shall have ten (10) days from receipt of said notice within
which to remedy said circumstances.

                  c. "Covered Period" means the time period commencing on the
date of and coincident with a Change of Control and ending one year thereafter.

                  d. "Determination Date" shall have the meaning set forth in
Section 2.a. hereof.

                  e. "Disability" means the inability of Employee to perform his
assigned duties for PPD for a period of three (3) months due to Employee's
physical or mental illness as determined by a reputable medical doctor.

<PAGE>

                  f. "PPD" means Pharmaceutical Product Development, Inc. and
all of its subsidiaries and affiliated entities.

                  g. "Termination for Cause" means (i) an act or acts involving
fraud, embezzlement or theft from PPD, (ii) Employee's willful and repeated
failure to follow directions of the Board of Directors that continues for at
least ten (10) days following written notice of the Board of Directors of such
failure to follow directions, or (iii) termination for cause as defined in and
made pursuant to a then effective employment agreement, if any, between Employee
and PPD.

         2. Compensation Upon Change of Control. If during the Covered Period
(i) PPD terminates Employee's employment for reason other than Termination for
Cause or (ii) Employee's employment is terminated by reason of Constructive
Termination, Employee shall be entitled to the following compensation and
benefits:

                  a. PPD shall pay Employee a lump sum equal to Employee's W-2
compensation for the twelve (12) months ending on the last day of the month
preceding the month of Employee's termination (the "Determination Date"), said
sum to be paid within ten (10) days after Employee's termination of employment.
If Employee has been employed by PPD for less than twelve (12) months determined
as of the Determination Date, Employee shall be paid a lump sum equal to the
quotient of the total compensation to which Employee is entitled to W-2 purposes
for the period beginning on date Employee commenced employment with PPD and
ending on the Determination Date, divided by a fraction, the numerator of which
shall be the number of days Employee has been employed by PPD ending on the
Determination Date and the denominator of which is 365.

                  b. PPD shall pay Employee any bonus or deferred compensation
(whether in the form of cash, stock or otherwise) accrued but unpaid as of
Employee's termination, said sum to be paid within ten (10) days after
Employee's termination of employment.

                  c. For a period of twelve months after Employee's termination
of employment with PPD, PPD shall continue to pay for and provide existing
employee welfare benefits which Employee is receiving as of the date of
termination of employment, including life insurance, health, medical, dental,
vision and wellness, accidental death and dismemberment and disability benefits;
provided, however, that PPD's obligations under this clause shall terminate from
the date that Employee first becomes eligible after termination of employment
with PPD for similar coverage under another employer's plan.

                  d. Notwithstanding anything to the contrary in any award
agreement for non-qualified stock options, (i) all unvested shares underlying
PPD non-qualified stock options granted more than six months prior to the date
of Employee's termination shall become fully vested as of the date of Employee's
termination, and (ii) Employee

                                       2
<PAGE>

shall continue to be treated under each award agreement as if he was an employee
of PPD until the first to occur of (x) the third anniversary of Employee's
termination of employment, or (y) the expiration of the exercise period provided
for therein; provided, however, in the event of Employee's death or his
disability (as disability is defined in the award agreement) after the date of
Employee's termination of employment hereunder, the time for exercise after
death or such disability prescribed in the award agreement shall apply. The
provisions of this subsection shall also apply to any and all substitute stock
options granted to Employee in exchange for Employee's PPD non-qualified stock
options to which this subsection applies.

         3.       Miscellaneous.

                  a. PPD will require any successor (whether direct or indirect,
by purchase, merger, consolidation or otherwise) to all or substantially all of
the business and/or assets of PPD, to expressly assume and agree to perform this
Agreement in the same manner and to the same extent that PPD would be required
to perform it if no succession had taken place.

                  b. This Agreement shall inure to the benefit of and be
enforceable by Employee's personal or legal representatives, executives,
administrators, successors, heirs, distributees, devisees and legatees.

                  c. For purposes of this Agreement, notices and all other
communications provided for in the Agreement shall be in writing and shall be
given (i) by certified mail, return receipt requested, postage prepaid, or (ii)
by recognized overnight carrier, and shall be deemed received when actually
received. Notices shall be addressed as follows:

                  If to PPD:            Pharmaceutical Product Development, Inc.
                                        3151 South 17th  Street
                                        Wilmington, North Carolina  28412
                                        Attention:    Chief Executive Officer

                  If to Employee:       Philippe M. Maitre
                                        3151 South Seventeenth Street
                                        Wilmington, North Carolina  28412

Either party hereto may change the notice address by giving notice thereof in
the same manner as provided for herein.

                  d. No waiver by either party hereto at any time of any breach
by the other party hereto of, or compliance with, any provision or condition of
this Agreement

                                       3
<PAGE>

to be performed by such other party shall be deemed a subsequent waiver of the
same or similar provisions or conditions.

                  e. No agreements or representations, oral or otherwise,
expressed or implied, with respect to the subject matter hereof have been made
by either party which are not set forth expressly in this agreement, and this
Agreement supersedes and replaces in its entirety all prior agreements and
representations, expressed, implied, oral or otherwise, made by PPD to or with
Employee.

                  f. This Agreement shall be governed by and interpreted under
the laws of the State of North Carolina.

                  g. The invalidity or unenforceability of any provision of this
Agreement shall not affect the validity or enforceability of any other provision
of this Agreement.

                  h. This Agreement may be executed in one or more counterparts,
each of which shall be deemed an original but all of which together shall
constitute one and the same instrument.

                  i. All legal expenses incurred by Employee in the successful
enforcement of any of the terms of this Agreement shall be paid by PPD.

                          [NEXT PAGE IS SIGNATURE PAGE]

         IN WITNESS WHEREOF, the parties have executed this Agreement effective
the date first hereinabove set forth.

                                        PHARMACEUTICAL PRODUCT
                                        DEVELOPMENT, INC.

                                       4
<PAGE>

                                     By:      /s/  Fredric N. Eshelman
                                        ---------------------------------
                                     Name: Fredric N. Eshelman
                                     Title: Chief Executive Officer

                                     EMPLOYEE

                                              /s/  Philippe M. Maitre     (SEAL)
                                     --------------------------------------
                                     Name: Philippe M. Maitre

                                       5EXHIBIT 10.150

                                 FIRST AMENDMENT

         THIS FIRST AMENDMENT dated as of June 22, 2000 (the "Amendment"), to
the Loan Agreement referenced below, is by and among PPGx, Inc., a Delaware
corporation (the "Borrower"), Pharmaceutical Product Development, Inc., a North
Carolina corporation (the "Company"), and First Union National Bank
(the "Bank").

                              W I T N E S S E T H:
                              - - - - - - - - - -

         WHEREAS, pursuant to that certain Loan Agreement dated as of February
1, 1999 (as supplemented, amended and modified, the "Loan Agreement"; terms used
but not otherwise defined herein shall have the meanings provided in the Loan
Agreement) among the Borrower, the Company and the Bank, the Bank has agreed to
provide the Borrower with an $8 million revolving credit facility;

         WHEREAS, the Borrower has requested certain modifications to the Loan
Agreement including, without limitation, an increase in the size of the credit
facility to $9 million; and

         WHEREAS, the Bank has agreed to make the requested modifications on the
terms and conditions set forth herein;

         NOW, THEREFORE, IN CONSIDERATION of the premises and other good and
valuable consideration the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

         1.       The Loan Agreement is amended in the following respects:

         1.1      The definition of "Termination Date" in Section 1. of the Loan
Agreement is amended to read as follows:

                  "Termination Date" means September 30, 2000.

         1.2      The first sentence of Section 2.1 of the Loan Agreement is
amended to read as follows:

                  During the Commitment Period, subject to the terms and
                  conditions hereof, the Bank agrees to make revolving loans to
                  the Borrower upon request in an aggregate principal amount of
                  up to (a) prior to June 30, 2000, NINE MILLION DOLLARS
                  ($9,000,000) at any time outstanding, and (b) on and after
                  June 30, 2000, ONE MILLION DOLLARS ($1,000,000) at any time
                  outstanding (the "Committed Amount").

         1.3      Section 2.7 is amended to read as follows:

                  2.7      Prepayments.

                           (a) Voluntary Prepayments. The Borrower may prepay
                  the Loans in whole or in part without premium or penalty.
                  LIBOR Rate Loans may not be prepaid in whole or in part prior
                  to the end of the applicable Interest Period. Amounts prepaid
                  may, subject to the terms and conditions hereof, be
                  reborrowed.

<PAGE>

                           (b) Mandatory Prepayments. If at any time the
                  aggregate principal amount of Loans shall exceed the Committed
                  Amount, the Borrower shall immediately make payment on the
                  Loans in an amount sufficient to eliminate the excess.

         2.       This Amendment shall be effective as of the date set forth
above upon satisfaction of the following conditions:

                  (a)      execution of this Amendment by the Borrower, the
         Company and the Bank;

                  (b)      execution of an amended and restated Note by the
         Borrower in the form attached hereto as Exhibit A; and

                  (c)      receipt by the Bank of a legal opinion of counsel to
         the Borrower and the Company in the form attached hereto as Exhibit B.

                                       2
<PAGE>

         3. The Borrower hereby represents and warrants that as of the date
hereof the representations and warranties contained in Section 5 of the Loan
Agreement (except for those which expressly relate to an earlier date) are true
and correct in all material respects.

         4. The Company (i) acknowledges and consents to all of the terms and
conditions of this Amendment, (ii) affirms all of its obligations under the
Credit Documents and (iii) agrees that this Amendment and all documents executed
in connection herewith do not operate to reduce or discharge the its obligations
under the Loan Agreement or the other Credit Documents.

         5. This Amendment may be executed in any number of counterparts, each
of which when executed and delivered shall be deemed to be an original and it
shall not be necessary in making proof of this Amendment to produce or account
for more than one such counterpart.

         6. Except as modified hereby, all of the terms and provisions of the
Loan Agreement and the other Credit Documents remain in full force and effect.

         7. The Borrower agrees to pay all reasonable costs and expenses in
connection with the preparation, execution and delivery of this Amendment,
including, without limitation, the reasonable fees and expenses of Moore & Van
Allen, PLLC, special counsel to the Bank.

         8. This Amendment shall be governed by, and construed in accordance
with, the laws of the State of North Carolina.

            [The remainder of this page is intentionally left blank.]

                                       3
<PAGE>

         IN WITNESS WHEREOF, each of the parties hereto has caused this First
Amendment to be duly executed and delivered as of the date first above written.

BORROWER:                           PPGx, Inc.,
                                    a Delaware corporation

                                    By: /s/ Joshua S. Baker
                                       --------------------
                                    Name: Joshua S. Baker
                                    Title: President & CEO

COMPANY:                            PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.,
                                    a North Carolina corporation

                                    By: /s/ Fredric N. Eshelman
                                       ------------------------
                                    Name: Fredric N. Eshelman
                                    Title:  CEO

BANK:                               FIRST UNION NATIONAL BANK

                                    By: /s/ G. Mendel Lay, Jr.
                                       -----------------------
                                    Name:  G. Mendel Lay, Jr.
                                    Title:  Sr. V.P.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}]]